Avicenna.AI States Stroke Detection AI Tool Approved for Medicare NTAP

November 24, 2020

Avicenna.AI today announced that its CINA Head software qualifies for the new technology add-on payment (NTAP) recently approved by the Centers for Medicare & Medicaid Services (CMS).

The NTAP is available for radiological computer-assisted triage and notification software systems like CINA Head, which analyze computed tomography angiogram (CTA) images of the brain acquired in acute settings, and urgently notifies clinical team members when a suspected large vessel occlusion (LVO) has been identified to reduce time to treatment.

Dr. Peter Chang, radiologist, and co-founder of Avicenna.AI, said, “AI-enabled CT stroke triage, specifically with LVO detection, is the first deep learning tool to receive the CMS NTAP designation and is eligible for up to $1040 of reimbursement. CMS only grants NTAP designation to promote the adoption of new technology that provides substantial clinical improvement over standard of care. This will help accelerate the innovation and adoption of deep learning technology by aligning the incentives of both software developers and clinical providers.”

In addition to LVO detection, Avicenna‘s FDA-approved CINA Head triage AI solution for neurovascular emergencies also detects intracranial hemorrhages (ICHs). Using a combination of deep learning and machine learning technologies, CINA Head automatically detects and prioritizes acute ICH and LVO cases from CT-scan imaging within 20 seconds, seamlessly alerting the radiologist within their existing systems and workflow.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version